Advances in molecular oncology have revealed that specific genetic changes in tumor cells can drive cancer growth and influence how patients respond to treatment. Among these, MET gene alteration in non-small cell lung cancer has become a clinically significant area of research and targeted therapy development. Understanding these alterations helps clinicians choose more precise treatment strategies and gives patients a clearer picture of their diagnosis.
Key Takeaways
- MET gene alterations, including exon 14 skipping mutations and amplification, are established oncogenic drivers in NSCLC.
- MET exon 14 skipping mutations occur in approximately 3–4% of NSCLC cases, while MET amplification is more variable in frequency.
- FDA-approved MET-targeted therapies such as capmatinib and tepotinib are available for eligible patients.
- Molecular testing via NGS, FISH, or IHC is essential to identify the specific type of MET alteration before selecting therapy.
- Prognosis and treatment response vary depending on alteration type, co-mutations, and prior therapies.
MET Gene Alteration in Non-Small Cell Lung Cancer (NSCLC) FAQs
The MET proto-oncogene alteration lung cancer category encompasses several distinct molecular events that abnormally activate the MET signaling pathway. The MET gene encodes a receptor tyrosine kinase known as the hepatocyte growth factor receptor (HGFR). When functioning normally, this receptor regulates cell growth, survival, and migration. When altered through mutation, amplification, or overexpression, it can promote uncontrolled tumor proliferation and resistance to standard therapies.
Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer diagnoses worldwide, according to the American Cancer Society. Within this population, a meaningful subset harbors MET alterations that qualify for targeted intervention. Identifying these alterations through genomic profiling is now a standard recommendation in major oncology guidelines, including those from the National Comprehensive Cancer Network (NCCN), because the alteration type directly determines which treatment pathways are most appropriate.
Clinicians often encounter patients who have progressed after first-line therapies and are later found to have MET alterations either as primary drivers or as acquired resistance mechanisms. This dual role makes MET one of the more complex—but increasingly actionable—targets in thoracic oncology. Routine molecular profiling at diagnosis and at disease progression is therefore recommended to capture the full landscape of MET-related changes.
MET Exon 14 Skipping and MET Amplification: Key Alteration Types Explained
Two of the most clinically relevant categories of MET gene changes in NSCLC are MET exon 14 skipping mutations and MET amplification, each with a distinct molecular mechanism and therapeutic implication.
MET exon 14 skipping mutation lung cancer refers to a splice-site alteration that causes the region encoded by exon 14 to be omitted during messenger RNA processing. Exon 14 encodes a domain that regulates MET receptor degradation; when this domain is absent, the receptor accumulates on the cell surface in an active state, driving continuous downstream signaling. This mutation occurs in roughly 3–4% of NSCLC cases and is more commonly observed in older patients and in tumors with sarcomatoid histology, based on data published in the Journal of Clinical Oncology.
MET amplification NSCLC treatment options depend on how the amplification is categorized. MET amplification refers to an increase in the copy number of the MET gene within tumor cells, which leads to overproduction of the MET receptor protein and excessive pathway activation. It can occur as a primary oncogenic event in a small percentage of de novo NSCLC cases or, more frequently, as an acquired resistance mechanism in patients previously treated with EGFR tyrosine kinase inhibitors. High-level amplification (typically defined as a MET-to-CEP7 ratio ≥5 by fluorescence in situ hybridization) is more predictive of response to MET-targeted agents than low-level amplification or polysomy.
| Alteration Type | Mechanism | Approximate Frequency in NSCLC | Clinical Context |
|---|---|---|---|
| MET Exon 14 Skipping | Splice-site mutation causes loss of degradation domain | 3–4% | Primary driver; often de novo |
| MET Amplification (high-level) | Increased MET gene copy number | 1–5% primary; up to 15–20% post-EGFR TKI resistance | Primary or acquired resistance |
| MET Overexpression | Elevated protein without gene copy number change | Variable | Less predictive; under active study |
Understanding the distinction between these alteration types is essential for treatment planning. Patients with exon 14 skipping mutations and those with high-level MET amplification have shown meaningful clinical responses to approved MET inhibitors, whereas patients with low-level amplification or protein overexpression alone have shown inconsistent results in clinical trials. Therapeutic decisions therefore hinge on precise molecular subtyping rather than a general MET-positive designation.
MET-Targeted Therapy Options and Their Impact on NSCLC Prognosis
MET targeted therapy for non-small cell lung cancer has progressed substantially with the FDA approval of selective MET inhibitors. Capmatinib (Tabrecta) received FDA approval in 2020 for adults with metastatic NSCLC whose tumors harbor a MET exon 14 skipping mutation, followed by tepotinib (Tepmetko) in 2021 for the same indication. Both are oral MET kinase inhibitors that block aberrant MET signaling, and both demonstrated clinically meaningful overall response rates in their pivotal trials—GEOMETRY mono-1 for capmatinib and VISION for tepotinib.
Crizotinib, originally developed as an ALK inhibitor, also has MET-inhibitory activity and has been used off-label or within clinical trials for MET-driven NSCLC. However, newer selective MET inhibitors generally offer improved potency and tolerability profiles compared to crizotinib for MET-specific indications. Ongoing trials are evaluating combination strategies, including pairing MET inhibitors with EGFR-targeted agents in patients whose resistance to EGFR therapy is driven by MET amplification.
Regarding prognosis, MET exon 14 skipping mutations have historically been associated with a shorter median overall survival compared to other oncogene-driven NSCLC subtypes when treated with conventional chemotherapy. The introduction of selective MET inhibitors has meaningfully improved outcomes for this group, with median progression-free survival reported in the range of 12–13 months in treatment-naive patients in pivotal studies. For MET amplification-driven resistance, combining a MET inhibitor with a continued or modified EGFR inhibitor has shown early promise in extending disease control. Prognosis ultimately depends on the alteration type, tumor stage, presence of co-mutations, and the patient’s overall performance status.
How MET Gene Alterations Are Detected and What Results Mean for Treatment
Accurate identification of a MET gene change requires biomarker testing performed on tumor tissue or, in some cases, liquid biopsy. The choice of testing method matters because different assays capture different types of alterations with varying sensitivity and specificity.
Next-generation sequencing (NGS) panels are widely considered the most comprehensive approach, as they can detect exon 14 skipping mutations, amplification, point mutations, and fusions simultaneously. RNA-based NGS is particularly sensitive for splice-site alterations such as exon 14 skipping, because DNA-based panels may miss certain splice variants. Fluorescence in situ hybridization (FISH) is the standard method for quantifying MET gene copy number and assessing amplification levels. Immunohistochemistry (IHC) can measure MET protein expression but is less specific as a standalone test for predicting treatment response.
Interpreting Test Results in Clinical Practice
When a pathology report identifies a MET exon 14 skipping mutation, it indicates eligibility for FDA-approved selective MET inhibitor therapy and should prompt referral to a thoracic oncologist or molecular tumor board. A result showing high-level MET amplification in a patient who has progressed on an EGFR inhibitor signals an acquired resistance mechanism that may be addressable with MET-targeted combination strategies.
Low-level MET amplification or MET overexpression without confirmed gene-level changes requires careful clinical interpretation, as the evidence supporting targeted therapy in these cases is less robust. Multidisciplinary review of molecular results is strongly advised before finalizing a treatment decision, particularly when the alteration falls into a borderline or ambiguous category.
The Role of Liquid Biopsy in MET Alteration Testing
Liquid biopsy, which analyzes circulating tumor DNA (ctDNA) from a blood sample, offers a non-invasive alternative when tissue biopsy is not feasible or when serial monitoring is needed. While liquid biopsy sensitivity for MET exon 14 skipping detection has improved significantly, tissue biopsy remains the gold standard when sufficient material is available. Liquid biopsy is particularly useful for capturing acquired MET amplification at the time of disease progression, where re-biopsy may be logistically challenging.
Frequently Asked Questions
Are MET gene alterations hereditary in NSCLC?
MET gene alterations found in NSCLC tumors are almost always somatic, meaning they arise in lung cells during a person’s lifetime rather than being inherited. They are driven by environmental exposures, replication errors, or prior treatments rather than passed from parent to child. Germline MET mutations do exist but are associated with hereditary papillary renal carcinoma rather than inherited lung cancer risk. Standard tumor molecular testing does not assess germline status; a separate germline panel would be required for hereditary risk evaluation.
Can patients with MET alterations receive immunotherapy?
Immunotherapy with PD-1 or PD-L1 checkpoint inhibitors has generally shown limited efficacy as monotherapy in NSCLC driven by specific oncogenic mutations, including MET exon 14 skipping. Tumor mutational burden tends to be lower in these tumors, which reduces immunotherapy responsiveness. However, individual cases vary, and clinicians may consider immunotherapy in combination with other agents within clinical trials. Current guidelines prioritize MET-targeted therapy as the preferred first-line approach when an actionable MET alteration is confirmed.
What happens if a patient develops resistance to MET inhibitors?
Resistance to MET inhibitors can develop through multiple mechanisms, including secondary MET mutations (such as the D1228 or Y1230 mutations), bypass signaling through KRAS, EGFR, or other pathways, and MET gene amplification at higher levels. Clinical trials are actively investigating next-generation MET inhibitors and combination strategies designed to overcome these resistance mechanisms. Upon disease progression on a MET inhibitor, repeat molecular testing through tissue or liquid biopsy is recommended to identify the resistance driver and guide subsequent therapy selection.
